LeMaitre Vascular, Inc. (NASDAQ:LMAT) Declares Quarterly Dividend of $0.25

Key Points

• Dividend: LeMaitre declared a quarterly dividend of $0.25 per share payable June 4 (record date May 21), implying a $1.00 annual payout and about a 0.9% yield; the company has raised its dividend for 14 consecutive years and the payout ratio is around 42%.
• Results & guidance: LeMaitre beat Q1 EPS estimates at $0.68 (revenue up 11.1% year-over-year) and issued FY2026 guidance of $2.93–$3.08 EPS with Q2 guidance of $0.79–$0.84.
• Insider sales & ownership: CEO George W. LeMaitre sold 150,000 shares for about $16.0M, insiders sold ~215,438 shares (~$23.1M) in the last quarter, and institutional investors own roughly 84.6% of the stock after several large funds increased stakes.

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) announced a quarterly dividend on Tuesday, May 5th. Investors of record on Thursday, May 21st will be given a dividend of 0.25 per share by the medical instruments supplier on Thursday, June 4th. This represents a c) annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Thursday, May 21st.

LeMaitre Vascular has increased its dividend payment by an average of 0.2%annually over the last three years and has raised its dividend every year for the last 14 years. LeMaitre Vascular has a payout ratio of 42.0% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect LeMaitre Vascular to earn $3.19 per share next year, which means the company should continue to be able to cover its $1.00 annual dividend with an expected future payout ratio of 31.3%.

Get LeMaitre Vascular SMS alerts:

Sign Up

LeMaitre Vascular Stock Up 0.4%

NASDAQ:LMAT opened at $112.00 on Wednesday. The firm's 50 day simple moving average is $109.28 and its 200 day simple moving average is $94.17. The company has a debt-to-equity ratio of 0.43, a current ratio of 12.89 and a quick ratio of 10.95. LeMaitre Vascular has a one year low of $78.35 and a one year high of $118.01. The company has a market cap of $2.56 billion, a PE ratio of 44.62, a P/E/G ratio of 3.21 and a beta of 0.60.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 EPS for the quarter, topping the consensus estimate of $0.66 by $0.02. The business had revenue of $66.55 million for the quarter, compared to the consensus estimate of $66.67 million. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 14.72%. The firm's revenue was up 11.1% compared to the same quarter last year. During the same period last year, the company earned $0.48 EPS. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. On average, research analysts anticipate that LeMaitre Vascular will post 2.89 earnings per share for the current year.

Insider Activity at LeMaitre Vascular

In related news, CEO George W. Lemaitre sold 150,000 shares of the business's stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $106.76, for a total transaction of $16,014,000.00. Following the transaction, the chief executive officer owned 1,532,304 shares in the company, valued at $163,588,775.04. The trade was a 8.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David B. Roberts sold 8,464 shares of the business's stock in a transaction on Friday, February 27th. The shares were sold at an average price of $106.80, for a total transaction of $903,955.20. Following the transaction, the director owned 17,979 shares in the company, valued at $1,920,157.20. The trade was a 32.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 215,438 shares of company stock worth $23,062,911 in the last quarter. Company insiders own 7.40% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in LMAT. M&T Bank Corp raised its stake in LeMaitre Vascular by 2,240.5% during the 4th quarter. M&T Bank Corp now owns 398,069 shares of the medical instruments supplier's stock worth $32,283,000 after buying an additional 381,061 shares during the period. Goldman Sachs Group Inc. raised its stake in LeMaitre Vascular by 144.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 391,254 shares of the medical instruments supplier's stock worth $31,731,000 after buying an additional 231,157 shares during the period. First Trust Advisors LP raised its stake in LeMaitre Vascular by 35.4% during the 3rd quarter. First Trust Advisors LP now owns 828,947 shares of the medical instruments supplier's stock worth $72,541,000 after buying an additional 216,919 shares during the period. Millennium Management LLC raised its stake in LeMaitre Vascular by 119.8% during the 1st quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier's stock worth $17,722,000 after buying an additional 115,141 shares during the period. Finally, Geode Capital Management LLC raised its stake in LeMaitre Vascular by 20.1% during the 4th quarter. Geode Capital Management LLC now owns 633,089 shares of the medical instruments supplier's stock worth $51,351,000 after buying an additional 105,921 shares during the period. 84.64% of the stock is owned by institutional investors and hedge funds.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company's offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre's product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.